Candriam S.C.A. Cuts Holdings in Amgen Inc. $AMGN

Candriam S.C.A. lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 12.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 445,220 shares of the medical research company’s stock after selling 60,500 shares during the period. Amgen makes up 0.7% of Candriam S.C.A.’s portfolio, making the stock its 27th biggest position. Candriam S.C.A. owned about 0.08% of Amgen worth $125,641,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Legacy Investment Solutions LLC acquired a new stake in Amgen during the 2nd quarter worth approximately $27,000. Evelyn Partners Investment Management LLP purchased a new stake in Amgen during the second quarter worth approximately $32,000. Howard Hughes Medical Institute purchased a new stake in Amgen during the second quarter worth approximately $32,000. Quaker Wealth Management LLC increased its position in shares of Amgen by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after acquiring an additional 240 shares in the last quarter. Finally, Cloud Capital Management LLC purchased a new position in shares of Amgen in the 3rd quarter valued at $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 4.5%

NASDAQ:AMGN opened at $384.20 on Monday. The stock has a market cap of $206.88 billion, a price-to-earnings ratio of 27.00, a price-to-earnings-growth ratio of 3.96 and a beta of 0.46. Amgen Inc. has a one year low of $261.43 and a one year high of $385.12. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The business’s 50-day simple moving average is $334.45 and its 200 day simple moving average is $311.51.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the business earned $5.31 EPS. Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a $2.52 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio is currently 66.90%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. This represents a 14.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. The trade was a 30.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 10,908 shares of company stock worth $3,674,966 in the last ninety days. 0.69% of the stock is owned by insiders.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research reports. HSBC reaffirmed a “buy” rating and set a $425.00 price target on shares of Amgen in a research report on Wednesday, December 10th. Oppenheimer set a $400.00 price objective on Amgen and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Morgan Stanley upped their target price on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. Truist Financial raised their target price on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a report on Thursday, January 8th. Finally, UBS Group boosted their price target on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $351.65.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.